Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)

Nadav Kimelman,Joseph Berger,Ehud Marom,Laura Popper,Uri Danon,Aaron Miller,Shai Rubnov

doi:10.1212/wnl.0000000000202948

Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)

Nadav Kimelman, Joseph Berger + Show 5 more

https://doi.org/10.1212/wnl.0000000000202948

Copy DOI

Journal: Neurology

Publication Date: Apr 25, 2023

Affiliation: Mapi Research Trust, Mapi Pharma (Israel), University of Pennsylvania, Icahn School of Medicine at Mount Sinai

#Relapsing Forms Of Multiple Sclerosis #Long-Acting Injection + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)

Full Text